A Double Blind Study to Investigate the Clinical Efficacy and Safety of TreeMATAMPL (Allergy Therapeutics, (UK) Ltd.), TreeMATA (Allergy Therapeutics, (UK) Ltd.) and Placebo in Patients With Seasonal Allergic Rhinitis Due to Birch Pollen Allergy, in an Environmental Exposure Chamber (EEC) Model When Exposed to Birch Pollen and Oak Pollen
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2007
At a glance
- Drugs Birch pollen allergy immunotherapy; Monophosphoryl lipid A
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- 11 Sep 2007 Status changed from recruiting to suspended.
- 03 Dec 2006 New trial record.